Migraine pain is often accompanied by symptoms such as nausea, fatigue, and vision changes, and the debilitating, throbbing discomfort can bring daily life to an abrupt halt. Groundbreaking research reveals new findings Migraine preventive medicine – atogepant – From the first day of use, it can provide instant relief to those suffering.
A study published in the online edition of the American Academy of Neurology Journal of Neurology found that people taking atogepant were less likely to experience a migraine on the first day than those taking a placebo. In addition to this, subjects who took the new drug experienced fewer migraines than participants in the placebo group weekly for the first four weeks and throughout the study.
Study author Richard B. Lipton, M.D., Ph.D., of Albert Einstein College, said, “Many current medications to prevent migraine require time to find the right dose for the individual, and it takes time to find the most effective dose. It could take weeks or even months.” He is an M.D. in the Bronx, New York, and a Fellow of the American Academy of Neurology. “Some people give up and stop taking their medication before they get to this point. Additionally, many people experience side effects with current treatments. It’s important to develop drugs that are effective and fast-acting. is.”
Learn more about the research
The study, conducted over a 12-week period, was divided into three trials based on symptoms to understand the safety and effectiveness of the drug atogepant. People with episodic migraine endured up to 14 days of migraine each month, whereas people with chronic migraine experienced at least 15 days of headache each month, with at least 8 of those days meeting migraine criteria. I was there.
The Advanced trial included people with episodic migraines, with 222 given the drug and 214 given a placebo.
The Elevate trial involved paroxysmal migraine patients who had not responded to other oral prophylactic treatments. 151 people in this group received the drug and 154 received a placebo.
In the Progress trial of chronic migraine patients, 256 people received the drug and 246 received a placebo.
In the Advance trial, 12% of participants who took the drug experienced a migraine on the first day, compared with 25% in the placebo group. In the “promotion” trial, 15% were in the drug group and 26% in the placebo group. In the “Advance” trial, 51% of those taking the drug reported migraine headaches, compared to 61% of those in the placebo group.
After adjusting for factors that may affect the incidence of migraines, the researchers found that the drug reduced the likelihood of migraine by 61% in the “Advance” trial, 47% in the “Elevate” trial, and ” In the “Progression” trial, they found a 37% reduction.
In terms of migraine days, participants who took atogepant in the first two trials had an average of one fewer migraine day per week, while those in the placebo group had less than half a migraine day. In the third trial, the number of migraine days decreased by about 1.5 days per week in the group taking the drug, compared to about 1 day per week in the placebo group.
People taking atogepant also experienced an improvement in overall quality of life compared to people taking a placebo.
“Migraines are the second leading cause of disability in the overall population and the leading cause of disability among young women, with people reporting a negative impact on their relationships, parenting, careers and finances. ,” Lipton said. “We need treatments that can quickly and effectively address critical needs.”
What is a migraine?
A migraine is more than just a severe headache; it comes with a variety of symptoms that vary from person to person. But the most debilitating of all the symptoms is the irritating headache that is often experienced on one side of the head and recurs many times. migraine symptoms These include nausea, vomiting, mood changes, extreme fatigue, and sensitivity to light, noise, and smell. These symptoms may occur all at once during a migraine attack, or they may occur separately during a migraine attack. Migraine attacks can last from a few hours to a few days, making daily life difficult.
Headaches range in intensity from moderate to severe. It is usually a throbbing or pulsating sensation.
According to current research, this headache occurs when there are abnormalities in nerve signals, chemical signals, and blood vessel activity in the brain.
migraine triggers
Common migraine triggers can include menstruation or the start of a menstrual cycle. Between attacks, people with migraines may experience symptoms such as difficulty concentrating, depression or anxiety, fatigue, difficulty sleeping, and body chills.
Some people experience changes in their vision during a migraine attack, such as seeing dots, zigzags, or sparks. There may also be changes in a person’s ability to speak. It may also include a tingling sensation in different parts of the body.
(Photo courtesy of iStock)
